Sumie Koike - Concepedia

Concepedia

Author

Sumie Koike

Japanese Foundation For Cancer Research

Also Known As

Koike, Sumie, Sumie Koike

37

Publications

1.6K

Citations

15

H-Index

21

Concepts

All Affiliations

Japanese Foundation For Cancer Research The University of Tokyo Massachusetts General Hospital The Cancer Institute Hospital Harvard University

SK

About

Sumie Koike is an author at Japanese Foundation For Cancer Research specializing in medicine, tumor biology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	234
2	Cell Biology	4	4	234
3	Immunology	2	2	97
4	Pathology	1	1	83
5	Pharmacology	1	1	73

Sumie Koike

×

16

Publications

1.6K

Citations

15

H-Index

	Year	Citations
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib Ryohei Katayama, Luc Friboulet, Sumie Koike, Clinical Cancer Research	2014	285
Platelets Promote Tumor Growth and Metastasis via Direct Interaction between Aggrus/Podoplanin and CLEC-2 Satoshi Takagi, Shigeo Sato, Tomoko Oh‐hara, PLoS ONE	2013	205
Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer Ryohei Katayama, Yuka Kobayashi, Luc Friboulet, Clinical Cancer Research	2014	198
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer Ryohei Katayama, Takuya Sakashita, Noriko Yanagitani, EBioMedicine	2015	139
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models Ryohei Katayama, Bo Gong, Noriko Togashi, Nature Communications	2019	135
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance Koutaroh Okada, Mitsugu Araki, Takuya Sakashita, EBioMedicine	2019	125
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response Kana Sakamoto, Ryohei Katayama, Reimi Asaka, Leukemia Hematological MalignancyMalignant Blood DisorderImmunologyDrug ResponseRecurrent 8Q24	2018	83
Dofequidar fumarate sensitizes cancer stem‐like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP‐mediated drug export Ryohei Katayama, Sumie Koike, Shigeo Sato, Cancer Science PharmacotherapyCancer BiologyTumor BiologyDrug ResistanceCancer Cell Biology	2009	73
PRMT5, a Novel TRAIL Receptor-Binding Protein, Inhibits TRAIL-Induced Apoptosis via Nuclear Factor-κB Activation Hiroshi Tanaka, Yutaka Hoshikawa, Tomoko Oh‐hara, Molecular Cancer Research	2009	69
AP-1-Dependent miR-21 Expression Contributes to Chemoresistance in Cancer Stem Cell-Like SP Cells Aya Misawa, Ryohei Katayama, Sumie Koike, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics Tumor BiologySystems BiologyOncologyAp-1-dependent Mir-21 ExpressionMedicine	2010	64

Page 1